Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns) / Hercessi™ (trastuzumab-strf) - March 2026
Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastu
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once. Within each IPR, claims are counted only once, whether they are challenged under § 102, § 103, or both. Claims in litigations are determined based on claims alleged to be infringed or... By: Venable LLP
Related News
Website Tracking Technologies Under Scrutiny: A New Liability Frontier Under the DOJ Bulk Data Transfer Rule
Unknown19 minutes ago
DOUBLE THE YUM?: Alleged Unsolicited Marketing Texts Get Omaha Steaks into a TCPA Class Action–And the Wolf is Hungry!
Unknown34 minutes ago
January 2026 Litigation Update: Consumer Litigation Activity Remains Elevated Entering the New Year
Unknown36 minutes ago